My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Dabrafenib (GSK2118436)
    Dabrafenib (GSK2118436)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1004
    CAS #: 1195765-45-7 Purity ≥98%

    Description: Dabrafenib (formerly known as GSK2118436; GSK-2118436; GSK-2118436A; GSK-2118436B. Trade name: Tafinlar) is a novel, specific, orally bioavailable inhibitor of BRAF V600 mutants with potential anticancer activity. It inhibits BRAF V600 with an IC50 of 0.8 nM in cell-free assays and is 4- and 6-fold less potent against B-Raf (wildype) and c-Raf, respectively. Dabrafenib potently inhibits BRAF V600 mutants such as BRAFV600E, BRAFV600K and BRAFV600D with IC50 values of 0.5nM, 0.6nM and 1.9nM, respectively. Dabrafenib is currently approved by FDA and is widely used in cancer patients harboring BRAF mutations. It is reported that treatment of dabrafenib shrinks the overall size of brain metastases in patients. Dabrafenib FDA gained approval in 2013 to treat melanoma.

    References: Arch Pharm Res. 2011 May;34(5):699-701.

    Related CAS#: 1195768-06-9 (mesylate)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)519.56
    FormulaC23H20F3N5O2S2
    CAS No.1195765-45-7(free base);
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 30 mg/mL (57.74 mM)
    Water: <1 mg/mL (slightly soluble or insoluble)
    Ethanol: <1 mg/mL
    Solubility (In vivo)30% PEG400+0.5% Tween80+5% Propylene glycol: 8 mg/mL
    SynonymsGSK2118436A; GSK-2118436B; GSK 2118436A; GSK2118436B (Dabrafenib Mesylate ); GSK-2118436A; GSK 2118436B. Trade name: Tafinlar.



    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    GeneralDabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice.
    Animal modelA375P cells were implanted subcutaneously in female CD1 nu/nu mice and grown to form tumors [1]; Dabrafenib (orally gavage) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice [2].
    FormulationDissolved in 0.5% hydroxypropylmethylcellulose, 0.2% Tween 80 in pH 8.0 distilled water
    Dosages10, 30, and 100 mg/kg
    AdministrationAdministered orally once daily
    Reference[1] PLoS One. 2013; 8(7): e67583; [2] Sylvie Laquerre, et al. 2009, EORTC International Conference. Abst B88.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Dabrafenib (GSK2118436)

    Dabrafenib inhibits MAPK signalling in BRAFV600E cells and is abrogated by ARAF or CRAF depletion. PLoS One. 2013; 8(7): e67583.

    Dabrafenib (GSK2118436)

    Modulation of pharmacodynamic markers by dabrafenib in BRAFV600E tumors.

    Dabrafenib (GSK2118436)

    Inhibition of BRAFV600E tumor xenograft growth by dabrafenib.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?